VIRTUS Clinical Trial | 12-Month Data1

Pivotal Cohort 12-Month Primary Safety and Efficacy Results of the VICI Venous Stent System.


Assess safety & effectiveness in achieving patency of target venous lesion through 12 months post stent placement, in patients with obstruction of the iliofemoral venous outflow tract.


Trial Design

Prospective, multi-center (22 sites in the US and Europe) single arm, non-randomized.

Key Inclusion Criteria

Unilateral, clinically significant, chronic non-malignant obstruction of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof

  • ≥50% reduction in target vessel lumen diameter (venogram) Clinically significant venous obstruction defined as: CEAP “C” ≥3 OR VCSS Pain ≥2


Baseline Characteristics

VIRTUS Baseline Characteristics - Patient Demographics
VIRTUS Baseline Characteristics - Clinical Assessment

VIRTUS Clinical Trial | Efficacy Results


Primary patency rate at 12 months post-intervention

  • Freedom from occlusion by thrombosis
  • Freedom from surgical or endovascular intervention on target vessel which are found to have re-stenosis or stent occlusion to maintain patency
  • Freedom from in-stent stenosis more than 50% by venogram


Primary endpoint was met2

Primary patency rate exceeded the performance goal of 72.1% (p<0.0001)3,4

VIRTUS 12-Month Primary Patency Rate chart
VICI Venous Stent System Etiology

VIRTUS Clinical Trial | 12-Month Results


12-Month Results

Safety Results:

98.8% freedom from MAEs through 30 days

Primary endpoint was met2:

Safety rate exceeded the performance goal of 94%5


Patient Outcomes:

  • VIRTUS demonstrated a clinically meaningful 4.4 decrease in the VCSS score from baseline out to 12 months.
  • Vici shifted patients with a severe VCSS score from almost 66% down to 27%,and increased the patients in the mild VCSS score 4-fold.
  • 84% of patients experienced VCSS improvement.
VCSS charts

VIRTUS Clinical Trial | Conclusions


VIRTUS primary safety and effectiveness endpoints successfully met:

84% 12-month primary patency
98.8% freedom from MAE through 30 days



Patient sample with challenging characteristics

VIRTUS Challenging Patient Characteristics



Stay in-the-know

Stay in-the-know

Subscribe now to receive venous stent updates.

Get to know more

Get to know more

From expert opinions to fact sheets, find what you need to help educate your patients.